Advanced

Treatment delay and prognosis in invasive bladder cancer.

Liedberg, Fredrik LU ; Anderson, Harald LU and Månsson, Wiking LU (2005) In The Journal of urology 174(5). p.1777-1781
Abstract
Purpose: We studied treatment delay, and the impact on disease specific survival and stage progression in a series of patients who had undergone cystectomy. Materials and Methods: All 141 patients underwent radical cystectomy between 1990 and 1997 due to locally advanced bladder cancer. Treatment delay was defined as time from pathological confirmation of invasive disease to performance of cystectomy, and was registered retrospectively from the patient charts. Two patients received neoadjuvant chemotherapy and were excluded from further analyses. Followup continued until April 2003 with death due to bladder cancer as the end point. Causes of death were retrieved from the Swedish Cause of Death Registry. Results: The median treatment delay... (More)
Purpose: We studied treatment delay, and the impact on disease specific survival and stage progression in a series of patients who had undergone cystectomy. Materials and Methods: All 141 patients underwent radical cystectomy between 1990 and 1997 due to locally advanced bladder cancer. Treatment delay was defined as time from pathological confirmation of invasive disease to performance of cystectomy, and was registered retrospectively from the patient charts. Two patients received neoadjuvant chemotherapy and were excluded from further analyses. Followup continued until April 2003 with death due to bladder cancer as the end point. Causes of death were retrieved from the Swedish Cause of Death Registry. Results: The median treatment delay was 49 days, but was significantly longer for the 71 cases who were referred from other hospitals (63 Vs 41 days, p < 0.001). Treatment delay did not influence cumulative incidence of death from bladder cancer. Considering all cases, there was no significant correlation between treatment delay and stage progression. For clinical stage T2 tumors, median treatment delay was 76 days among patients with stage progression compared to 41 and 48 days for those with stage regression and stage equivalence, respectively (p=0.20). Conclusions: Treatment delay was not found to influence disease specific survival in the present study. Furthermore, treatment delay was not significantly longer in cases that progressed compared to those with equal or lower pathological stage in the cystectomy specimen. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
therapeutics, disease progression, appointments and, schedules, bladder neoplasms
in
The Journal of urology
volume
174
issue
5
pages
1777 - 1781
publisher
Lippincott Williams & Wilkins
external identifiers
  • wos:000232619700016
  • pmid:16217282
  • scopus:27544507285
ISSN
1527-3792
DOI
10.1097/01.ju.0000177521.72678.61
language
English
LU publication?
yes
id
59d24026-bdee-44bb-9668-a64f20de35e2 (old id 144711)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16217282&dopt=Abstract
date added to LUP
2007-07-23 14:13:41
date last changed
2017-07-30 04:46:52
@article{59d24026-bdee-44bb-9668-a64f20de35e2,
  abstract     = {Purpose: We studied treatment delay, and the impact on disease specific survival and stage progression in a series of patients who had undergone cystectomy. Materials and Methods: All 141 patients underwent radical cystectomy between 1990 and 1997 due to locally advanced bladder cancer. Treatment delay was defined as time from pathological confirmation of invasive disease to performance of cystectomy, and was registered retrospectively from the patient charts. Two patients received neoadjuvant chemotherapy and were excluded from further analyses. Followup continued until April 2003 with death due to bladder cancer as the end point. Causes of death were retrieved from the Swedish Cause of Death Registry. Results: The median treatment delay was 49 days, but was significantly longer for the 71 cases who were referred from other hospitals (63 Vs 41 days, p &lt; 0.001). Treatment delay did not influence cumulative incidence of death from bladder cancer. Considering all cases, there was no significant correlation between treatment delay and stage progression. For clinical stage T2 tumors, median treatment delay was 76 days among patients with stage progression compared to 41 and 48 days for those with stage regression and stage equivalence, respectively (p=0.20). Conclusions: Treatment delay was not found to influence disease specific survival in the present study. Furthermore, treatment delay was not significantly longer in cases that progressed compared to those with equal or lower pathological stage in the cystectomy specimen.},
  author       = {Liedberg, Fredrik and Anderson, Harald and Månsson, Wiking},
  issn         = {1527-3792},
  keyword      = {therapeutics,disease progression,appointments and,schedules,bladder neoplasms},
  language     = {eng},
  number       = {5},
  pages        = {1777--1781},
  publisher    = {Lippincott Williams & Wilkins},
  series       = {The Journal of urology},
  title        = {Treatment delay and prognosis in invasive bladder cancer.},
  url          = {http://dx.doi.org/10.1097/01.ju.0000177521.72678.61},
  volume       = {174},
  year         = {2005},
}